Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 489-493

  Messadi Laribi, E ^a,b   Griol Charhbili, V ^a,b   Gaies, E ^a   Vincent, M P ^a   Heudes, D ^a,c   Meneton, P ^a   Alhenc Gelas, F ^a,c   Richer, C ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Acute myocardial infarction; Angiotensin converting enzyme inhibition; AT1 receptor blockade; AT2 receptor; B2 receptor; Genetically modified mouse; Ischaemic preconditioning; Kallikrein kinin system; Tissue kallikrein

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ B1 RECEPTOR; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; LOSARTAN; RAMIPRILAT; SSR 240612; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; GENETIC ENGINEERING; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; KALLIKREIN KININ SYSTEM; LEFT CORONARY ARTERY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPERFUSION; TREATMENT OUTCOME;

EID: 40149108924     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04902.x     Document Type: Conference Paper

References (31)

1. 1 Hearse DJ, Bolli R. Reperfusion induced injury: Manifestations, mechanisms, and clinical relevance. Cardiovasc. Res. 1992 ; 26: 101–8.
2. 2 Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986 ; 74: 1124–36.
3. 3 Gross ER, Gross GJ. Ligand triggers of classical preconditioning and postconditioning. Cardiovasc. Res. 2006 ; 70: 212–21.
4. 4 Oldenburg O, Qin Q, Krieg T et al. Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am. J. Physiol. Heart Circ. Physiol. 2004 ; 286: H468–76.
5. 5 Chao J, Chao L. Kallikrein‐kinin in stroke, cardiovascular and renal disease. Exp. Physiol. 2005 ; 90: 291–8.
6. 6 Bergaya S, Meneton P, Bloch‐Faure M et al. Decreased flow‐dependent dilation in carotid arteries of tissue kallikrein‐knockout mice. Circ. Res. 2001 ; 88: 593–9.
7. 7 Azizi M, Boutouyrie P, Bissery A et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J. Clin. Invest. 2005 ; 115: 780–87.
8. 8 Griol‐Charhbili V, Messadi‐Laribi E, Bascands JL et al. Role of tissue kallikrein in the cardioprotective effects of ischaemic and pharmacological preconditioning in myocardial ischaemia. FASEB J. 2005 ; 19: 1172–4.
9. 9 Witherow FN, Dawson P, Ludlam CA, Fox KA, Newby DE. Marked bradykinin‐induced tissue plasminogen activator release in patients with heart failure maintained on long‐term angiotensin‐converting enzyme inhibitor therapy. J. Am. Coll. Cardiol. 2002 ; 40: 961–6.
10. 10 Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002 ; 360: 752–60.
11. 11 Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin‐converting enzyme inhibitor. Circulation 1982 ; 65: 40–48.
12. 12 Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin‐converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 1996 ; 27: 7–13.
13. 13 Martorana PA, Kettenbach B, Breipohl G, Linz W, Scholkens BA. Reduction of infarct size by local angiotensin‐converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J. Pharmacol. 1990 ; 182: 395–6.
14. 14 Meneton P, Bloch‐Faure M, Hagege AA et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein‐deficient mice. Proc. Natl Acad. Sci. USA 2001 ; 98: 2634–9.
15. 15 Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein‐kinin system is present in rat hearts. Hypertension 1994 ; 23: 919–23.
16. 16 Emanueli C, Madeddu P. Targeting kinin receptors for the treatment of tissue ischaemia. Trends Pharmacol. Sci. 2001 ; 22: 478–84.
17. 17 Tschope C, Heringer‐Walther S, Walther T. Regulation of the kinin receptors after induction of myocardial infarction: A mini‐review. Braz. J. Med. Biol. Res. 2000 ; 33: 701–8.
18. 18 Xu J, Carretero OA, Sun Y et al. Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. Hypertension 2005 ; 45: 747–53.
19. 19 Sato M, Engelman RM, Otani H et al. Myocardial protection by preconditioning of heart with losartan, an angiotensin II type 1‐receptor blocker: Implication of bradykinin‐dependent and bradykinin‐independent mechanisms. Circulation 2000 ; 102 (Suppl. 3): III346–51.
20. 20 Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: Unraveling the ARB‐MI paradox. Circulation 2006 ; 114: 838–54.
21. 21 Trabold F, Pons S, Hagege AA et al. Cardiovascular phenotypes of kinin B2 receptor‐ and tissue kallikrein‐deficient mice. Hypertension 2002 ; 40: 90–5.
22. 22 Gougat J, Ferrari B, Sarran L et al. SSR240612 [(2R)‐2‐[(3R)‐3‐(1,3‐benzodioxol‐5‐yl)‐3‐[[(6‐methoxy‐2‐naphthyl) sulfonyl]amino]propanoyl) amino]‐3‐(4‐[[2R,6S)‐2,6‐dimethylpiperidinyl]methyl]pheny (l)‐N‐isopropyl‐N‐methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: Biochemical and pharmacological characterization. J. Pharmacol. Exp. Ther. 2004 ; 309: 661–9.
23. 23 Linz W, Wiemer G, Scholkens BA. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes 1996 ; 45 (Suppl. 1): S51–8.
24. 24 Bumpus FM, Catt KJ, Chiu AT et al. Nomenclature for angiotensin receptors. A report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension 1991 ; 17: 720–21.
25. 25 Michael LH, Entman ML, Hartley CJ et al. Myocardial ischemia and reperfusion: A murine model. Am. J. Physiol. 1995 ; 269: H2147–54.
26. 26 Messadi‐Laribi E, Griol‐Charhbili V, Pizard A et al. Tissue kallikrein is involved in the cardioprotective effect of AT1‐receptor blockade in acute myocardial ischemia. J. Pharmacol. Exp. Ther. 2007 ; 323: 210–16.
27. 27 Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size reduction by AT1‐receptor blockade through a signal cascade of AT2‐receptor activation, bradykinin and prostaglandins in pigs. J. Am. Coll. Cardiol. 1998 ; 32: 1787–96.
28. 28 Siragy HM, De Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan‐induced hypotension in conscious rats. Hypertension 2000 ; 35: 1074–7.
29. 29 Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin‐dependent mechanism. Hypertension 1998 ; 31: 349–55.
30. 30 Hecquet C, Tan F, Marcic BM, Erdos EG. Human bradykinin B(2) receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 2000 ; 58: 828–36.
31. 31 Slim R, Torremocha F, Moreau T et al. Loss‐of‐function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J. Am. Soc. Nephrol. 2002 ; 13: 968–76.